BUZZ - Torm shares decline as Oaktree exits in a $253.5 million secondary offering

路透社2026/10/06 12:11

Show original

Updated Pricing Details: On October 6th, before the market opened on Tuesday, shares of the tanker operator Torm (TRMD.O), listed in the US, dropped 3.2% to $39.72 after the company announced the pricing of its secondary offering. According to the company (link), funds managed by Oaktree Capital Management sold approximately 6.3 million shares, raising a total of about $253.5 million. The secondary offering was priced at $40.05 per share, a 2.4% discount to the stock's previous closing price. According to the prospectus, Oaktree Capital completely exited its remaining approximately 6.2% stake following the sale (link). JPMorgan served as the sole underwriter for this issuance. Last month, Oaktree Capital (link) sold shares in another secondary offering of 9 million shares at $32.25 per share. Driven by record freight rates, the shares of tankers listed in Northern Europe (link) have soared, and Torm's stock closed up 2.6% on Monday at $41.05. As of Monday’s close, the company’s US-listed shares had surged about 110% year-to-date, including a 47% gain over the past three months. (For the convenience of non-English speakers, Reuters provides its report with automated translation into several languages. Due to the possibility of errors or the lack of contextual accuracy from automated translation, Reuters does not guarantee the accuracy of these texts. The automated translation is provided for readers’ convenience only. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Updated pricing details

October 6 - ** Before the market opened on Tuesday, shares of product tanker operator Torm (TRMD.O) listed in the US fell 3.2% to $39.72 after the company announced its secondary offering price

** The company stated (link) that funds managed by Oaktree Capital Management sold about 6.3 million shares, raising a total of approximately $253.5 million

** The offering was priced at $40.05, a 2.4% discount to the previous trading day's closing price

** According to the prospectus, following this sale, Oaktree Capital has sold off its remaining approximately 6.2% stake (link)

** JPMorgan served as the sole underwriter for this offering

** Last month, Oaktree Capital (link) sold shares through a secondary offering of 9 million shares at a price of $32.25 per share

** Buoyed by record freight rates, shares of tanker companies listed in Northern Europe (link) rose; Torm's share price closed up 2.6% on Monday at $41.05

** As of Monday's close, the company's US-listed shares have soared about 110% so far this year, with a 47% gain in the past three months

(To facilitate non-native English speakers, Reuters automatically translates its reports into several other languages. As automated translation may contain errors or may not contain the required context, Reuters does not guarantee the accuracy of the automated translation text and provides automated translation solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation feature.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26